Top Markets
Coin of the day
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Rank in Stocks #28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$0.4
Last synced: 2026-10-02
Market Cap
$27.18M
Change (1 day)
-14.88%
Change (1 year)
8.11%
Country
US
Trade Cell Source, Inc. (CLCS)

Category

EPS for Cell Source, Inc. (CLCS)
EPS as of 2026 TTM: 0
According to Cell Source, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Cell Source, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$-7.98 -
US
$-5.29 -
AU
$27.74 -
NL
- -
CH